Search
Glecaprevir
go.drugbank.com/drugs/DB13879ApprovedInvestigationalIn cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA … The combinations of amino acid substitutions at NS3 position Y65H and D/Q168 also results in greater reductions in glecaprevir susceptibility, and NS3 Q80R in genotype 3a patients also leads to glecaprevir
Categories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsConcizumab
go.drugbank.com/drugs/DB12820ApprovedInvestigationalConcizumab is a humanized IgG4 monoclonal antibody targeting the Kunitz-2 domain of tissue factor pathway inhibitor (TFPI), a key regulator of the coagulation cascade. … [L52043] By inhibiting TFPI, concizumab enhances the production of factor Xa via the extrinsic clotting pathway.
Selenium
go.drugbank.com/drugs/DB11135ApprovedInvestigationalVet approvedSelenium is a trace metal in the human body particularly important as a component of glutathione peroxidase, an important enzyme in the prevention of cellular damage by free radicals and reactive oxygen
Mixtures: Liquid Opti-minplex +d, L-Methyl PNV DHACategories: Compounds used in a research, industrial, or household settingFerric pyrophosphate
go.drugbank.com/drugs/DB09147ApprovedInvestigationalFerric pyrophosphate is an iron replacement product. Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. The ferric ion is st...
Mixtures: Escavite LqGuanabenz
go.drugbank.com/drugs/DB00629ApprovedWithdrawnGuanabenz is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.
Avapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigational[A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure
Synonyms: DP-VPALU-31130
go.drugbank.com/drugs/DB05828ExperimentalLU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders. … It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors.
Gastric intrinsic factor
go.drugbank.com/drugs/DB09349ApprovedIntrinsic factor (IF), also known as gastric intrinsic factor (GIF), is a glycoprotein produced by the parietal cells of the stomach that is necessary for the absorption of vitamin B12 (cobalamin) later
Mixtures: EnLyte Extra-LN